Viralii Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.20 M
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 580.68%
- Profit Growth 136.11%
- Ebitda -240.16%
- Net Worth 48.30%
- Total Assets 183.62%
About Viralii Life Sciences
Viralii Life Sciences Private Limited (VLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 April 2018 (Six years and ten months 17 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Vinay Khandelwal and Arup Roy serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74999GJ2018PTC101675
- Company No.
101675
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Apr 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Viralii Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinay Khandelwal  | Director | 06-Apr-2018 | Current |
| Arup Roy | Director | 06-Apr-2018 | Current |
Financial Performance of Viralii Life Sciences.
Viralii Life Sciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 580.68% increase. The company also saw a substantial improvement in profitability, with a 136.11% increase in profit. The company's net worth Soared by an impressive increase of 48.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Viralii Life Sciences?
In 2019, Viralii Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aukea Life Sciences Private LimitedVinay Khandelwal is a mutual person
- Auracare Pharma Private Limited
Vinay Khandelwal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Viralii Life Sciences?
Unlock and access historical data on people associated with Viralii Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Viralii Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Viralii Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.